The National Institutes of Health (NIH) has announced a funding opportunity titled "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine" (PAR-23-267) aimed at supporting the development of novel extracellular vesicle (EV)-based therapeutic platforms. This initiative specifically invites U.S. small businesses to apply for Small Business Innovation Research (SBIR) grants, focusing on overcoming challenges in the production and manufacturing of EVs for tissue and organ repair, with an emphasis on demonstrating GMP-grade production and facilitating regulatory approval. The funding mechanism includes cooperative agreements (U43/U44), with a budget cap of $295,924 for Phase I and $1,972,828 for Phase II awards, and applications must adhere to stringent guidelines and undergo peer review. Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with the application deadline set for June 6, 2025.